Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Posted: September 27, 2024 at 2:51 am

SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist in development for the proposed treatment and long-term maintenance therapy of acromegaly.

Read more here:
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Related Posts